The
new OTC market company Drive Bio-tech had an online roadshow on January 8 and the
company plans to launch an initial public offering on January 11.
Drive
Bio-tech is a hematopoietic feed manufacturer and is also the only company in
China to mainly produce hematopoietic products. The hematopoietic products made
from Drive Bio-tech have avoided the disadvantages that traditional
hematopoietic nutrition products have had and will lower the frequency of
anemia in livestock, which often occurs when raising animals in close quarters,
so as to increase the survival rate of livestock. The company has established
close cooperation with several major customers such as Royal DSM, Haid Group, DBN Sci-tech, Aonong Biological Technology
Group Corporation, Tongwei Co., Ltd., Huaying Agricultural Development Co., Ltd,
and New Wellful Co., Ltd.
Drive Bio-tech is mainly
engaged in the research production and marketing of hematopoietic
feed products. The company’s main product is hematopoietic feed additive premix
and additive premixes of other functions.
Drive Bio-tech with an improved
approach to treating anemia in livestock
Hematopoietic products
are mainly used to address the problem of anemia in livestock, which can occur
when animals are raised in close proximity to one another. Blood is one of the
essential materials in animals, as it helps animals’ growth, improve animals’
immune systems, increase animals’ blood content, as well as improve animals’flesh
color. The use of hematopoietic products in pigs will also reduce the economic
loss caused by bad quality of pork, increase sows’ reproducing ability, as well
as increase higher survival rate of piglets.
Animal anemia is one of
the common problems faced by those who raise livestock. According to Anne
Mette Scrunz Hanl’s article from the magazine Pigs and Poultry, surveys
from the United States, Denmark, Canada, and Norway have shown that under the
condition of commercialization, 20% of piglets have iron deficiency anemia and
their MCHC is below 90g/L and more than 75% of the pigs’ MCHC in pig farms is
below 110g/L.
The
traditional hematopoietic
products are not very effective and very dangerous. According to the public
offering prospectus of Drive Bio-tech, the traditional hematopoietic products contain
arsenic, which can cause widened blood vessels, so as to mask animals’ dark
yellow skin and unhealthy flesh color caused by anemia. In addition, arsenic is
poisonous to human beings and animals, and it pollutes the environment.
Drive Bio-tech constructs research institute and completes
product trials
Drive Bio-tech always
focuses on the research and development of their products. In 2017, the company
established a city-level research institution in Guangzhou, Guangdong. In the
meanwhile, the company also established a long term corporation with
educational institutions, such as South China Agricultural University, The
Institute of Subtropical Agriculture, and The Chinese Academy of Sciences.
Since the end of 2020, Drive Bio-tech has owned eight patents, with three
patents of invention.
Drive Bio-tech has
conducted trails of its hematopoietic products in
China’s representative pig farms in Nanjing, Hebei, Fujian, Jiangxi and
Guangxi. Data shows that Drive Bio-tech’s hematopoietic products
increase the number of qualified healthy piglets by 1.08 pigs per litter; increase
the average litter weight by 1.88 kg/litter; decrease litter
delivery time by 59.22 mins/litter; and increase MCHC by 13.4% and 13.3% for
sows and piglets, respectively.
For more information, please check our resources
on China’s
feed market.